The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Miki Sogi - Sanford C Bernstein & Co LLC - Analyst
: Thank you very much. First, at ASCO, you presented TL02 QCS analysis, looking at the data for AVANZAR study positive results can be expected
with higher confidence. On your end, doublet results were very good. If you look at the patient population and the dose being used, that was
different from the triplet cohort. Still, the results were very good. So based on these results, what kind of clinical studies are you going to proceed
in lung cancer with Datroway.
Unidentified Company Representative
Thank you for your question. You asked two questions. First, biomarker candidate and with the higher possibility or probability of development
of Datroway in lung cancer in NSCLC, if there is a biomarker, we have a higher probability that is a learning for us. That's how we see this. That's
one question to your -- answer to your question.
Next, doublet and triplet results were available and recruitment was not sufficient. So we are going to do more. But as for learning in both triplet
and doublet, there was sustained efficacy we are able to confirm. So treatment option is being expanded. DL07, 08, based on our ideas, we are
proceeding, including AVANZAR, kind of combination therapies are good, we'd like to discuss and based on the results, we'd like to proceed with
new clinical studies.
Did I answer your question?
Question: Miki Sogi - Sanford C Bernstein & Co LLC - Analyst
: Thank you.
Unidentified Company Representative
I will be now checking. Yes, for development, that will be discussed going forward.
|
